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Ovarian cancer, and clear cell carcinoma in particular, reportedly increases the risk of venous thromboembolism (VTE). However, the
mechanisms remain unclear. Tissue factor (TF) supposedly represents a major factor in the procoagulant activities of cancer cells.
The present study examined the involvement of TF expression in VTE for patients with ovarian cancer. Subjects comprised
32 consecutive patients (mean age 49.8 years) with histologically confirmed ovarian cancer. Presence of VTE was examined using a
combination of clinical features, D-dimer levels and venous ultrasonography. Immunohistochemical analysis was used to evaluate TF
expression into 4 degrees. Venous thromboembolism was identified in 10 of the 32 patients (31%), including five of the 11 patients
with clear cell carcinoma. Tissue factor expression was detected in cancer tissues from 24 patients and displayed significant
correlations with VTE development (P¼0.0003), D-dimer concentration (P¼0.003) and clear cell carcinoma (Po0.05). Multivariate
analysis identified TF expression as an independent predictive factor of VTE development (Po0.05). Tissue factor (TF) expression is a
possible determinant of VTE development in ovarian cancer. In particular, clear cell carcinoma may produce excessive levels of TF and
is more likely to develop VTE.
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Venous thromboembolism (VTE) is a common complication of
cancer (Baron et al, 1998; Lee and Levine, 2003). Since the first
description of an association between VTE and cancer by
Trousseau (1868), cancer has emerged as an important risk factor
for VTE. A prospective medical database of a county population in
the United States reported cancer alone as associated with a 4.1-
fold increase in risk of VTE, compared to the annual incidence
of a first episode of VTE in the general population of 117 out of
100000-capita (Silverstein et al, 1998; Heit et al, 2000). Conversely,
Sørensen et al (2000) reported that 1-year survival rate was
significantly lower in cancer patients with VTE (12%) than in
cancer patients without VTE (36%), and the mortality ratio
associated with VTE was 2.2 for the 1-year follow-up period. This
mortality probably reflects deaths owing to VTE, and VTE
complication may thus cause a life-threatening condition in cancer
patients. To improve survival rate for cancer patients, clarification
of the clinical characteristics and pathogenic mechanisms of VTE
with cancer is necessary.
Ovarian cancer is known to display a particular association with
VTE (Heit et al, 2000; von Tempelhoff et al, 2000). According to
data from Medicare International Classification of Disease, 9th
Revision (ICD-9) hospital discharge diagnoses between 1988 and
1990 in the United States, ovarian cancer exhibited the highest
incidence of cancer-related VTE, at 120 out of 10000 patients
(Levitan et al, 1999). Moreover, some reports have suggested that
clear cell carcinoma of the ovary is particularly likely to develop
VTE (Pather and Quinn, 2005). Yoonessi et al (1984) reported that
13.7% of patients with clear cell carcinoma of the ovary developed
thromboembolic complications. Recio et al (1996) reported an
11% incidence of symptomatic thromboembolic complications
with clear cell ovarian carcinoma. Although ovarian cancer, and
clear cell carcinoma in particular, seems more likely to result in
VTE, the pathological mechanisms remain speculative.
Regarding the mechanisms underlying VTE formation in cancer
patients, several tumour cell procoagulant activities have been
identified that may act at steps in blood coagulation pathways
(De Cicco, 2004). Numerous studies have suggested that tissue
factor (TF) may play an important role in the pathogenesis of
hypercoagulable states in patients with cancer (Rao, 1992), and TF
expression has been confirmed in some cancer tissues by
immunohistochemistry (Callander et al, 1992; Ueno et al, 2000).
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sHowever, correlations between TF expression in cancer tissues and
clinical VTE formation have not yet been proven.
The purpose of this study was to clarify the involvement of
TF expression in VTE with ovarian cancer, particularly clear cell
carcinoma. We also investigated relationships between TF expres-
sion and D-dimer concentration, as a marker of procoagulant
activity.
MATERIALS AND METHODS
Study population
All study protocols were approved by the Ethical Committee of
Tsukuba University Hospital. The study complied with the
principles of the Declaration of Helsinki. A total of 36 consecutive
patients with ovarian cancer admitted for initial treatment to the
Department of Gynecology and Obstetrics, Tsukuba University
Hospital, were enrolled in this study from January 2004. Only
patients with newly diagnosed ovarian cancer were included.
All patients provided written informed consent to participate in
the study. Patients were excluded if clinically significant renal,
hepatic or cardiac disease was present. A medical history was
taken for thromboembolic risk factors including: age, body mass
index (BMI), hypertension, diabetes mellitus, venous varicosities,
preoperative immobility and previous history of VTE. Medication
use was also documented for each patient, including oral hormonal
drugs. Clinical stages were determined according to the criteria
of the International Federation of Gynecology and Obstetrics
(FIGO), and histological classifications were also evaluated.
Haematological analysis and VTE diagnosis were performed
before any treatment. All patients underwent gynaecological
surgery, and immunohistochemical analysis was performed with
surgical tissue with the exception of biopsy tissue before
neoadjuvant chemotherapy. And all assessments including ultra-
sonography, immunohistochemical and pathological diagnoses,
were evaluated blinded to their diagnoses and haematological
analysis.
Haematological analysis
Before treatment, peripheral blood samples were collected from all
patients and D-dimer levels were measured. Blood samples were
drawn from an antecubital vein with atraumatic puncture into
plastic tubes using a two-tube technique, discarding the first
4–5ml. Whole blood was anticoagulated with the addition of 9
volumes to 1 volume of 3.2% sodium citrate solution, then
centrifuged at 3000r.p.m. for 10min. Citrate plasma was then
removed and frozen at  201C up to 3 days before assessment. D-
dimer levels were measured by latex photometric immunoassay
(Roche Diagnostics, Basel, Switzerland) (Kario et al, 1992).
Diagnosis of VTE
Presence of VTE was identified according to procedures recom-
mended elsewhere (Perrier et al, 1999; Andrews and Fleischer,
2000), using a combination of clinical features, D-dimer levels and
venous ultrasonography. Ultrasongraphic examination of leg veins
was performed for patients displaying symptoms of suspected VTE
or highly elevated levels of D-dimer (X3.0mgml
 1). Ultrasono-
graphy was performed using an ATL HDI5000 system (PHILIPS
Medical Systems, Bothell, WA, USA) equipped with a 3–7.5MHz
transducer according to the search site. The iliac, femoral,
popliteal, peroneal, post-tibial and soleal veins were evaluated in
both legs. Venous lumens were observed while searching for
thrombus by manual compression with transducer and colour
Doppler signals. For evaluation of intrapelvic veins, reactions
during a Valsalva manoeuvre were also observed. No reaction
during the Valsalva manoeuvre was considered to represent
suspected proximal venous flow disturbance, and intrapelvic deep
venous thrombosis (DVT) was diagnosed based on the results of
enhanced computer tomography. In addition, lung perfusion
scintigraphy was performed for patients with DVT, any symptoms
suggesting pulmonary thromboembolism (PTE) or low oxygen
saturation, to identify PTE.
Immunohistochemistry
To examine the association between TF expression and VTE, we
performed immunohistochemical assessment for all patients with
or without VTE. Surgical specimens were fixed in 10% formalin
and embedded in paraffin. Each tumour specimen was stained
on X3 separate occasions. Thin sections (3mm) were prepared,
deparaffinised with xylene and rehydrated in ethanol, then
endogenous peroxidase was blocked in 3% H2O2 in methanol for
15min. After washing in water, all sections were irradiated by
microwave for 5min in 10mM citrate buffer (pH 6.0). For the
immunoperoxidase method, sections were incubated with 1:50
diluted anti-human TF antibody (4509; American Diagnostica,
Stamford, CT, USA) overnight at 41C. Sections were further
incubated in biotinylated horse anti-mouse immunoglobulin-G
(IgG) (Vector ABC elite kit, Vector Laboratories, Burlingame,
CA, USA), followed by avidin–biotin–peroxidase complex
(ABC; Vector, Burlingame, CA, USA). Both biotinylated IgG and
ABC solutions were prepared with phosphate-buffered saline
containing 0.5% skim milk to eliminate the background
staining. Immunoreactions were visualised using diaminobenzi-
dine tetrahydrochloride.
For each set of staining experiments, positive and negative
controls were used. The positive control comprised a section of
umbilical cord, which is known to stain brightly for TF (Callander
et al, 1992), overlaid with anti-human TF IgG. Sections incubated
with normal mouse serum instead of the primary antibody served
as negative controls.
Intensity of TF expression was classified into four degrees
as follows: ( ), negative; (þ), weakly positive (o50% positive
tumour cells); (þþ), moderately positive (X50% positive tumour
cells with weak intensity); (þþþ), strongly positive (X50%
positive tumour cells with strong intensity), based on the
proportion of the entire tumour cell population showing
positive for TF (Hamada et al, 1996). Representative examples of
each score are presented in Figure 1. To diagnose with the tissue
after neoadjuvant chemotherapy, we used the region containing
enough amount of their original cancer cell structure to be
evaluated for pathological and immunohistochemical diagnoses.
All immunohistochemical and pathological assessments were
performed by three independent observers blinded to clinical
conditions.
Statistical analysis
To identify any prevalence effect for VTE development, Mann–
Whitney’s U-test was used for age and BMI, Spearman’s
correlation coefficient by rank was used for stage and TF
expression, and Fisher’s exact test (two-tailed) was used for
histological classification (clear cell carcinoma or not). For
multivariate analysis, logistic regression analysis was used to
examine the effects of TF expression on VTE development after
controlling for other clinically important risk factors such as age,
BMI, stage and histological classification.
To examine correlations with TF expression, Spearman’s
correlation coefficient by rank was used for age, BMI, D-dimer
level and stage, and Mann–Whitney’s U-test was used for
histological classification and presurgical chemotherapy.
Results are expressed as mean values (7s.d.) and values of
Po0.05 were considered statistically significant.
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Subject characteristics
A total of 36 consecutive untreated patients with stage I–IV
ovarian cancer were managed in this study period. Of these,
ovarian cancer could not be histologically confirmed in four
patients owing to damage from neoadjuvant chemotherapy, and
the remaining 32 patients with histological confirmed ovarian
cancer were enrolled in the final analysis. None of these 32 patients
had a previous history of VTE or use of hormonal drugs. Four
patients had received pharmacotherapy for hypertension and two
patients had received medical treatment for diabetes mellitus.
Table 1 shows patient characteristics. Mean age on initial
treatment was 49.8713.7 years (range 18–77 years) and mean
BMI was 23.374.2 (range 18.3–39.4). According to the findings at
major surgery, seven patients had stage I ovarian cancer, six
patients stage II, 11 patients stage III and eight patients stage IV.
Ovarian cancer specimens included 12 serous carcinomas, four
endometrioid carcinomas, 11 clear cell carcinomas, three un-
differentiated carcinomas, one mixed epithelial carcinoma and one
yolk sac tumour.
Before treatment, 14 patients underwent ultrasonographic
evaluation for VTE with abnormal D-dimer levels
(9.5977.27mgml
 1; Table 1), and three of these patients showed
symptoms of DVT, with leg pain in two patients and leg oedema in
one patient. None of the patients without abnormal D-dimer
elevation showed any symptoms. Of the 14 patients who under-
went ultrasonography, 10 patients (31%) developed DVT in the leg
veins. Pulmonary thromboembolism (PTE) was identified in four
of the 10 patients (one symptomatic; three asymptomatic). No
patients showed any symptom of suspected VTE in the absence of
elevated D-dimer levels. Deep venous thrombosis was located
proximal to the popliteal vein in four patients, but was limited to
AB
D C
Figure 1 Immunohistochemical staining of tissue factor in ovarian carcinoma tissues. (A) Negative control, ( ); (B) weakly positive (o50% positive
tumour cells), (þ); (C) moderately positive (X50% positive tumour cells with weak intensity), (þþ); (D) strongly positive (X50% positive tumour cells
with strong intensity), (þþþ), based on the proportion of the entire tumour cell population positive for TF. All pictures were taken at original
magnification  200.
Table 1 Patient characteristics (n¼32)
Mean7s.d.
Age (years) 49.8713.7
BMI 23.374.2
D-dimer (mgml
 1) 4.9276.32
Number of patients
FIGO stage
Stage I 7
Stage II 6
Stage III 11
Stage IV 8
Histological subtype
Serous 12
Endometrioid 4
Clear cell 11
Undifferentiated 3
Mixed epithelial 1
Yolk sac tumour 1
Underwent ultrasonography 14
BMI¼body mass index; FIGO¼International Federation of Gynecology and
Obstetrics.
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died from VTE, although one patient died of cancer during the
observational period.
Immunohistochemical study
Seventeen patients received neoadjuvant chemotherapy. Immuno-
histochemical analysis was performed with biopsy tissue before
neoadjuvant chemotherapy for two patients, and surgical tissue
after neoadjuvant chemotherapy for 15 patients.
A heterogeneous and studded pattern of TF staining was
observed within sections (Figure 1). Specimens were thus
evaluated semiquantitatively by calculating the percentage of
positively stained neoplastic cells, as described in Materials and
Methods. Tissue factor expression was detected in cancer tissues of
27 patients, including nine (þ), 10 (þþ) and eight (þþþ).
Tissue factor expression, demographic characteristics, results of
haematological examination, chemotherapy before surgery, stage,
and histological classification of subjects are summarised in
Table 2. A significant positive correlation between D-dimer level
and TF expression was observed (P¼0.0030, r¼0.533). No
significant correlations were noted between TF expression and
age, BMI or stage. Tissues from clear cell carcinoma exhibited
significantly stronger TF expression than tissues from non-clear
cell carcinoma (Po0.05).
Table 3 shows the comparison between patients with and
without VTE. A significant correlation was noted between intensity
of TF expression and occurrence of VTE (P¼0.0003, r¼0.653).
No significant differences were detected in age, BMI or stage.
Frequency of VTE was significantly higher in patients with clear
cell carcinoma (five of 11 patients; 45%) than in with non-clear cell
carcinoma patients (five of 21 patients; 24%). However, no
significant prevalence effect on VTE was identified for clear cell
carcinoma (P¼0.2515). Multivariate analysis detected age and
TF expression as significant determinant risk factors for VTE
development (P¼0.0352, r¼0.247 and P¼0.0347, r¼0.249,
respectively).
DISCUSSION
In this study, at least 31% (10 out of 32) of ovarian cancer patients
displayed DVT (symptomatic, n¼3; asymptomatic, n¼7) before
treatment, and 13% (four out of 32) had PTE (symptomatic, n¼1;
asymptomatic, n¼3). Tissue factor expression was significantly
stronger in patients with VTE than in patients without VTE
(P¼0.0003). Moreover, age and TF expression were also detected
as significant determinant risk factors for VTE (P¼0.0352 and
P¼0.0347, respectively) in multivariate analysis. Tissue factor
expression was significantly increased in the presence of elevated
D-dimer concentration (P¼0.003). In addition, clear cell carcino-
ma (n¼11) showed a high frequency of VTE (five out of 11; 45%)
and significantly stronger TF expression than non-clear cell
carcinoma (Po0.05). These results suggest that development of
VTE may be mediated by TF expression, and TF expression was
marked in clear cell carcinoma.
Table 2 Patient characteristics according to intensity of TF expression in cancer tissues
Intensity of TF expression
( ) n¼5 (+) n¼9 (++) n¼10 (+++) n¼8 P
(mean7s.d.)
Age (years) 51.078.1 48.8710.2 55.6714.4 42.9717.3 0.4407
BMI 25.073.2 24.776.1 22.773.6 21.571.9 0.0796
D-dimer (mgml
 1) 1.5070.93 1.5571.06 5.2873.85 10.479.94 0.0030
Neoadjuvant chemotherapy (number of subjects)
(+) (n¼15) 3 4 6 2 0.3387
FIGO stage (number of subjects)
Stage I (n¼7) 1 2 2 2 0.8034
Stage II (n¼6) 1 1 2 2
StageIII (n¼11) 1 4 3 3
Stage IV (n¼8) 2 2 3 1
Histological classification (number of subjects)
Non-clear cell 4 8 6 3 0.0391
Clear cell 1 1 4 5
A significant correlation existed between TF expression and D-dimer concentration (P¼0.003; r¼0.533). Tissue from clear cell carcinoma showed significantly stronger TF
expression than tissue from non-clear cell carcinoma (Po0.05). BMI¼body mass index; FIGO¼International Federation of Gynecology and Obstetrics; TF¼tissue factor.
Table 3 Comparison of clinical characteristics (age, BMI, stage,
histological classification) and intensity of TF expression between patients
with VTE (n¼10) and without VTE (n¼22)
VTE ( )
n¼22
VTE (+)
n¼10 P
(mean7s.d.)
Age (years) 47.9713.9 54.0712.9 0.0782
BMI 24.074.6 21.772.4 0.9171
FIGO stage (number of subjects)
Stage I (n¼7) 6 1 0.1065
Stage II (n¼6) 3 3
Stage III (n¼11) 8 3
Stage IV (n¼8) 5 3
Histological classification (number of subjects)
Non-clear cell (n¼21) 16 5 0.2515
Clear cell (n¼11) 6 5
Intensity of TF expression (number of subjects)
Negative (n¼5) 5 0 0.0003
Weakly positive (n¼9) 9 0
Moderately positive (n¼10) 5 5
Strongly positive (n¼8) 3 5
Patients with VTE showed significantly stronger TF expression (P¼0.0003;
r¼0.653). BMI¼body mass index; FIGO¼International Federation of Gynecology
and Obstetrics; TF¼tissure factor; VTE¼venous thromboembolism.
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in patients with ovarian cancer was high in the present
investigation. In fact, the report by Sallah et al (2002) described
symptomatic DVT in only four of 38 ovarian cancer patients
(11%). Our study, however, focused on asymptomatic DVT
patients and symptomatic DVT occurred in just three patients of
the 32 patients, compared with asymptomatic DVT in seven of 32
patients. Symptomatic DVT patients have been known to be
objectively far less common than in screening tests including
asymptomatic DVT patients (Kassaı ¨et al, 2004). Girard et al (1999)
reported that 82% of patients with acute PTE still displayed
detectable residual DVT at the time of PTE diagnosis, and DVT
remains asymptomatic in nearly two-thirds of PTE patients. To
prevent a clinical event such as PTE, identifying DVT in
asymptomatic patients is important. To find DVT in asymptomatic
patients, procedures using a combination of clinical features, D-
dimer levels and venous ultrasonography have been recommended
by various authors (Perrier et al, 1999; Andrews and Fleischer,
2000). D-dimer has been extensively investigated as a predictive
value for DVT, and reportedly displays high sensitivity (83–100%)
and negative predictive value (96–100%), although the specificity
of D-dimer is known to be low (35–70%) (Perrier and
Bounameaux, 2001; Righini et al, 2006). The sensitivity and
specificity of ultrasonography for the diagnosis of DVT have
been reported as 85–92 and 90–98%, respectively, and venous
ultrasonography has been described as the most accurate
noninvasive test for the diagnosis of DVT (Theodorou et al,
2003; Goodacre et al, 2005). A diagnostic algorithm using D-dimer
level as an initial test to rule out DVT and ultrasonography in
patients with abnormal D-dimer results has thus been proposed.
This noninvasive combined method seems useful for detecting
DVT in clinical situations.
Tissue factor, a transmembrane receptor lipophilic phospholipo-
protien with potent procoagulant activity, reportedly becomes
constitutively expressed in some cancer tissues (Rao, 1992; De
Cicco, 2004). Expression of TF on tumour cells, tumour-associated
macrophages and endothelial cells is upregulated in response to
cytokines, such as tumour necrosis factor and interleukin-1
(Grignani and Maiolo, 2000). Tissue factor initiates the extrinsic
pathway of the coagulation cascade by binding and activating factor
VII (FVII) and increasing the activity of activated FVII; these events
allow catalysis of factor X (FX) to activated FX, in turn activating
prothrombin to thrombin. For the mechanism of hypercoagulable
state in cancer, Szczepanski et al (1988) reported that the
procoagulant activities of cell extracts from gastric, colorectal and
renal cancers were FVII-dependent and could be related to the
presence of TF within cancer tissue. Although the procoagulant
activity promoted by TF might be the important process for
development of VTE in cancer patients, the correlation between TF
expression and VTE incidence had not been provided in previous
studies. The present investigation confirmed TF expression in
ovarian cancer tissues and evaluated the intensity of TF expression
semiquantitatively. We also searched for VTE including in
asymptomatic patients using US, and confirmed for the first time
that TF expression is significantly correlated with VTE development
in clinical situations. Procoagulant activity with D-dimer elevation
may be mediated by TF expression in ovarian cancer.
In addition, TF expression in cancer tissue has been suggested to
enhance transcription of vascular endothelial growth factor, which
stimulates angiogenesis, and thus to play a role in the cellular
signalling involved in the tumour growth and metastatic potential
of some cancers (Zhang et al, 1994). In ovarian cancer, Han et al
(2006) suggested TF as an independent predictive indicator of
prognosis. Conversely, Sørensen et al (2000) reported that survival
rate was significantly lower for cancer patients with VTE than for
cancer patients without VTE, and the mortality ratio associated
with VTE was 2.2 for the 1-year follow-up period. The present
investigation could not show the effect of TF expression or VTE
development on cancer progression owing to the limited observa-
tion period. Although we can speculate that procoagulant activity
and VTE affected by TF expression may cause cancer progression
in ovarian cancer patients, further investigations are needed to
clarify this relationship.
The influence of histological classification on TF expression was
shown, particularly for clear cell carcinoma. Clear cell carcinoma
is thought to display a Mu ¨llerian origin by the subsequent
association with endometriosis and endometrioid carcinoma
(Yoonessi et al, 1984). This rare tumour was recognised by the
World Health Organization as a distinct histological type in 1973
and accounts for p15% of all newly diagnosed ovarian cancers,
and some reports suggest that clear cell carcinoma of the ovary
is more likely to result in the development of VTE (Yoonessi
et al, 1984; Pather and Quinn, 2005). Although we could not
statistically confirm a prevalence effect of clear cell carcinoma,
five of 11 patients with clear cell carcinoma (45%) developed
pretreatment VTE, compared with 24% with non-clear cell
carcinoma. The mechanism underlying this high frequency of
VTE in the presence of clear cell carcinoma of the ovary are
unclear. In the present investigation, clear cell carcinoma
showed significantly stronger TF expression than non-clear cell
carcinoma (Table 2). This suggests that the high frequency of VTE
with clear cell carcinoma is likely to involve TF expression by
cancer tissues.
As a limitation of this study, the small sample size might affect
VTE incidence and a distribution of histological classification. And
also, the small sample size might be part of the reason that we
could not prove the direct relevance of clear cell carcinoma to VTE
incidence. Until the relevance is proven in a next investigation,
we could not recommend an intensive diagnostic test or an anti-
thrombosis therapy for patients with clear cell carcinoma. To
verify the relevance, further study with large number of patients
with ovarian cancer will be needed. Another limitation of this
study was that we could not address the alteration of TF expression
after chemotherapy. We diagnosed TF expression with the surgical
tissue after neoadjuvant chemotherapy for 15 patients among 32
patients. To reduce the misleading by the effect of neoadjuvant
chemotherapy, we used the region containing enough amount of
their original cancer cell structure for evaluation and observed
more amount of TF expression from the region. Therefore, we
assume cell function in the region, as well as its morphology, might
not be disturbed so much by neoadjuvant chemotherapy. However,
further investigation will be needed for evaluating the effect of
chemotherapy on cell function.
In conclusion, this study demonstrated a relation between TF
expression and clinical VTE development in patients with ovarian
cancer. In particular, clear cell carcinoma has the possibility of
producing excessive levels of TF and thus being more likely to
develop VTE.
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